000143359 001__ 143359
000143359 005__ 20240229112550.0
000143359 0247_ $$2doi$$a10.1038/s41416-019-0422-9
000143359 0247_ $$2pmid$$apmid:30894687
000143359 0247_ $$2ISSN$$a0007-0920
000143359 0247_ $$2ISSN$$a1532-1827
000143359 0247_ $$2altmetric$$aaltmetric:57407801
000143359 037__ $$aDKFZ-2019-00947
000143359 041__ $$aeng
000143359 082__ $$a610
000143359 1001_ $$0P:(DE-HGF)0$$aFortner, Renée$$b0$$eFirst author
000143359 245__ $$aSexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.
000143359 260__ $$aEdinburgh$$bNature Publ. Group$$c2019
000143359 3367_ $$2DRIVER$$aarticle
000143359 3367_ $$2DataCite$$aOutput Types/Journal article
000143359 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1576074868_25555
000143359 3367_ $$2BibTeX$$aARTICLE
000143359 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143359 3367_ $$00$$2EndNote$$aJournal Article
000143359 500__ $$a;120(8):855-860, mm
000143359 520__ $$aSexually transmitted infections (STIs) are associated with pelvic inflammatory disease and tubal pathologies. Given the tubal origin of a proportion of ovarian cancers, STIs may be relevant in their aetiology.Antibodies indicating past infection with Chlamydia trachomatis, Mycoplasma genitalium, herpes simplex virus type 2, and against human papillomavirus oncogenes (L1 and E6+E7 oncoproteins of types 16, 18, 45) were measured in prediagnosis plasma samples in a nested case-control study in the Nurses' Health Studies (n = 337 cases 1:1 matched to controls). Logistic regression was used to estimate multivariable-adjusted relative risks (RRs) and 95% confidence intervals [CIs] comparing women seropositive vs. seronegative among all cases (invasive and borderline), invasive (n = 257), and invasive serous ovarian cancers; n = 170), and borderline ovarian tumours (n = 80).C. trachomatis seropositivity was associated with higher risk of ovarian cancer overall (RR = 2.07 [1.25-3.43]); results were similar for invasive, invasive serous, and borderline tumours. We observed no associations for the other STIs. Relative to women seronegative to all infections, strongest associations were observed for seropositivity to C. trachomatis plus another STI (2.74 [1.20-6.27]; C. trachomatis alone, 1.88 [1.03-3.42]; all cases); however, the RRs were not significantly different.C. trachomatis infection may increase ovarian cancer risk; additional studies are required.
000143359 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000143359 588__ $$aDataset connected to CrossRef, PubMed,
000143359 7001_ $$aTerry, Kathryn L$$b1
000143359 7001_ $$0P:(DE-He78)540833b33724d8def638cce2f0b4e187$$aBender, Noemi$$b2
000143359 7001_ $$0P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2$$aBrenner, Nicole$$b3
000143359 7001_ $$0P:(DE-He78)87b3453102d0e45ec723d5a987d1f0e7$$aHufnagel, Katrin$$b4
000143359 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia$$b5
000143359 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b6
000143359 7001_ $$aTworoger, Shelley S$$b7
000143359 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-019-0422-9$$n8$$p855-860$$tBritish journal of cancer$$v120$$x1532-1827$$y2019
000143359 909CO $$ooai:inrepo02.dkfz.de:143359$$pVDB
000143359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000143359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)540833b33724d8def638cce2f0b4e187$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000143359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b1326dc42cbbc5f92b10fe5f254f0bc2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000143359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)87b3453102d0e45ec723d5a987d1f0e7$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000143359 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000143359 9141_ $$y2019
000143359 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143359 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143359 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143359 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000143359 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2017
000143359 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000143359 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000143359 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143359 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143359 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143359 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143359 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143359 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143359 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143359 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2017
000143359 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000143359 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lMolekulare Diagnostik Oncogener Infektionen$$x1
000143359 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x2
000143359 980__ $$ajournal
000143359 980__ $$aVDB
000143359 980__ $$aI:(DE-He78)C020-20160331
000143359 980__ $$aI:(DE-He78)F020-20160331
000143359 980__ $$aI:(DE-He78)F022-20160331
000143359 980__ $$aUNRESTRICTED